

Lipigon Q3 2023 - Stage set for Phase II

Redeye comments on Lipigon's Q3 report 2023. The main event since our last comment is the application to start the phase II trial which was submitted in November. The company also reported a statistically significant reduction of ANGPTL4 of 29% in the phase I study.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Lipigon Q3 2023 - Stage set for Phase II